Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;107(8):1928-1932.
doi: 10.3324/haematol.2021.280464.

Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma

Cyril Quivoron  1 , Anthony Tarabay  2 , Jean-Marie Michot  3 , Arnaud Pagès  4 , Hélène Lecourt  5 , Anne Aupérin  6 , Alina Danu  2 , Julien Lazarovici  2 , Julien Rossignol  2 , David Ghez  2 , Peggy Dartigues  7 , Véronique Vergé  7 , Christophe Massard  8 , Valérie Camara-Clayette  9 , Vincent Ribrag  10 , Clémentine Sarkozy  11
Affiliations

Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma

Cyril Quivoron et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Detection of tumor mutations in cell-free tumoral DNA. (A) Correlation between variant allele fraction (VAF) as assessed in cell-free tumoral DNA (ctDNA) sequencing or genomic DNA sequencing extracted from tumor biopsy (TB), and (B) level of similarity within most recurrently mutated genes, calculated for each gene as the percentage of TB variants found in ctDNA.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. - PMC - PubMed
    1. Maurer MJ, Ghesquières H, Jais JP, et al. . Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066-1073. - PMC - PubMed
    1. Sarkozy C, Sehn LH. New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Ann Lymphoma. 2019;3:10.
    1. Massard C, Michiels S, Ferté C, et al. . High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586-595. - PubMed
    1. Sarkozy C, Michot J, Quivoron C, et al. . Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B cell lymphoma, results of LNH‐EP1 study. Am J Hematol. 2021;96(10):E376-379. - PubMed

MeSH terms